<DOC>
	<DOCNO>NCT01180790</DOCNO>
	<brief_summary>Evaluate safety , tolerability antiviral response ACH-0141625 compare Standard Care HCV positive subject .</brief_summary>
	<brief_title>Safety , Tolerability Antiviral Activity ACH-0141625 Placebo Combination With Peginterferon Ribavirin HCV Positive Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Males females 18 year old Chronic hepatitis C Genotype 1 ( specify protocol ) Treatment naive Females postmenopausal amenorrheic must FSH screening . Females child bear potential must negative pregnancy test screen baseline . Females must use non hormonal method contraception must agree get pregnant study six month follow discontinuation SOC . Fertile male must agree use condom female partner must agree use one method contraception . Males must donate sperm study three month follow last exposure RBV . BMI &gt; 36 kg/m2 Pregnant nursing female : female childbearing potential willing comply contraceptive measure per protocol . Men whose female partner pregnant contemplate pregnancy . Coinfection HBV and/or HIV Other significant disease include liver disease History drug alcohol dependence addiction within past 6 month History participation clinical trial protease inhibitor previous treatment protease inhibitor , least one dose protease inhibitor consume . Use herbal homeopathic product , illicit drug , cytochrome P450 ( CYP 3A4/5 substrate , inducer inhibitor , hormonal method contraception , corticosteroid , immunosuppressive , cytotoxic agent within 28 day first dose study drug . Have clinically significant laboratory abnormality screening ( specify protocol ) . Segment 1 : Subjects history decompensated liver disease define cirrhotic subject ChildPugh score &gt; = 7 . Segment 2 : Subjects liver biopsy show bridge fibrosis cirrhosis . Nonalcoholic steatohepatitis ballooning degeneration Mallory body present liver biopsy . Subjects , prematurely discontinue , interrupt dose reduce prior PegIFN Ribavirin therapy , due noncompliance safety issue . Encephalopathy alter mental status etiology . History moderate , severe uncontrolled psychiatric disease ( specify protocol ) . History malignancy organ system treat untreated within past 5 year . Use colony stimulate factor agent within 90 day prior baseline . History seizure disorder . History know coagulopathy include hemophilia . Clinically significant finding fundoscopic retinal examination screen History immunologically mediate disease . History clinical evidence chronic cardiac disease ( specify protocol ) Received concomitant systemic antibiotic , antifungal antiviral treatment active infection within 14 day prior first dose study drug ( specify protocol )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
</DOC>